Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale.
The closely watched Alzheimer’s player is due to report key data expected in the coming months.
Prothena’s wholly owned programs include birtamimab for AL amyloidosis and a portfolio of programs for the potential treatment of Alzheimer’s disease, including PRX012 that targets Aβ (amyloid beta) and PRX123, the company’s dual Aβ-tau …
Gain insights, receive dynamic opportunities directly to your inbox. Sign up now…
Catalyzing Investor Engagement, InvestorHyve employs cutting-edge digital marketing solutions, advanced analytics, and an all-encompassing marketing and communications platform to revolutionize corporate interactions with stakeholders. Join us at InvestorHyve and step confidently into the future of corporate engagement
Ready to revolutionize your investor engagement strategy? Join InvestorHyve today and unlock a world of seamless connectivity, personalized interactions, and empowered investor relationships that drive success.
Copyright © 2024. All Rights Reserved.
